Monopoly

Soundbite Medical Solutions Announces Issuance of a Fourth U.S. Patent Further Expanding Coverage of its Core Technology

Retrieved on: 
Tuesday, July 27, 2021
Health, Medical devices, Cardiology, Monopoly, Patent law, Patent, United States patent law

It protects the novel Soundbite system architecture, which is used in all products of the company's burgeoning portfolio.

Key Points: 
  • It protects the novel Soundbite system architecture, which is used in all products of the company's burgeoning portfolio.
  • The patent is expected to expire in December 2036 and will continue to provide key intellectual property protection for the Company's technology platform.
  • This is the fourth US patent to be issued around the approved Soundbite technology.
  • Soundbite continues to enhance its patent portfolio with additional patent applications that will broaden and strengthen its patent protection in key markets throughout the world.

Universal Corporation Announces Conference Call

Retrieved on: 
Tuesday, July 27, 2021
Intellectual property law, Copyright, Monopoly, Product management, UVV, Information

RICHMOND, Va., July 27, 2021 /PRNewswire/ --Universal Corporation (NYSE:UVV) will webcast its conference call on August 4, 2021, following the release of its results for the first quarter of fiscal year 2022 after market close on that date.

Key Points: 
  • RICHMOND, Va., July 27, 2021 /PRNewswire/ --Universal Corporation (NYSE:UVV) will webcast its conference call on August 4, 2021, following the release of its results for the first quarter of fiscal year 2022 after market close on that date.
  • A replay of the webcast conference call will be available at that site through November 4, 2021.
  • The contents of the presentation are the property of Universal Corporation, protected by copyright law, and may not be reproduced in any form without the written permission of Universal Corporation.
  • Visit www.universalcorp.com for more information on Universal Corporation and the latest Company news.

RideCo Brings Patent Infringement Claims Against Via Transportation and Responds to Via's Meritless Lawsuit

Retrieved on: 
Tuesday, July 27, 2021
Monopoly, Patent, Via Transportation, Case law, Law

LOS ANGELES, Calif., July 27, 2021 /PRNewswire/ -RideCo, a leader in on-demand public transit solutions, today formally denied allegations made by Via Transportation ("Via") in a patent infringement lawsuit Via filed in the Western District of Texas, and RideCo brought its own patent infringement counterclaim against Via to protect RideCo's intellectual property.

Key Points: 
  • LOS ANGELES, Calif., July 27, 2021 /PRNewswire/ -RideCo, a leader in on-demand public transit solutions, today formally denied allegations made by Via Transportation ("Via") in a patent infringement lawsuit Via filed in the Western District of Texas, and RideCo brought its own patent infringement counterclaim against Via to protect RideCo's intellectual property.
  • RideCo is seeking an award of damages and an order permanently enjoining Via from further infringing RideCo's patents.
  • RideCo is a pioneer in the public transit technology space, launching North America's first on-demand public transit service in Milton, Ontario in April 2015.
  • The response further notes that at no point prior to the filing of Via's lawsuit did Via ever notify RideCo of its allegations of infringement.

Gamesys Group plc chooses 3radical to Deploy Free Online Gaming Experiences to Acquire and Retain Players

Retrieved on: 
Tuesday, July 27, 2021
Games, Gaming, Human activities, Gamification, Gamesys, Monopoly, Human behavior

BRISTOL, England, July 27, 2021 /PRNewswire/ -- 3radical , the leader in consumer data acquisition and audience engagement solutions, today announces it has signed a 5 year agreement with Gamesys Group plc, a leading international online gaming operator, to provide interactive gaming experiences to online players.

Key Points: 
  • BRISTOL, England, July 27, 2021 /PRNewswire/ -- 3radical , the leader in consumer data acquisition and audience engagement solutions, today announces it has signed a 5 year agreement with Gamesys Group plc, a leading international online gaming operator, to provide interactive gaming experiences to online players.
  • As one of the foremost online gaming operators, Gamesys' partnership with 3radical enables them to bring new and seasonal free-to-play gaming experiences to market using the 3radical Voco interactive gamification platform.
  • Already live with a "Monopoly" experience in Spain, these free-to-play games are key to attracting new players and bringing existing players back.
  • Gamesys Group plc is the parent company of an online group that provides entertainment to a global consumer base.

Gamesys Group plc chooses 3radical to Deploy Free Online Gaming Experiences to Acquire and Retain Players

Retrieved on: 
Tuesday, July 27, 2021
Games, Gaming, Human activities, Gamification, Gamesys, Monopoly, Human behavior

BRISTOL, England, July 27, 2021 /PRNewswire/ -- 3radical , the leader in consumer data acquisition and audience engagement solutions, today announces it has signed a 5 year agreement with Gamesys Group plc, a leading international online gaming operator, to provide interactive gaming experiences to online players.

Key Points: 
  • BRISTOL, England, July 27, 2021 /PRNewswire/ -- 3radical , the leader in consumer data acquisition and audience engagement solutions, today announces it has signed a 5 year agreement with Gamesys Group plc, a leading international online gaming operator, to provide interactive gaming experiences to online players.
  • As one of the foremost online gaming operators, Gamesys' partnership with 3radical enables them to bring new and seasonal free-to-play gaming experiences to market using the 3radical Voco interactive gamification platform.
  • Already live with a "Monopoly" experience in Spain, these free-to-play games are key to attracting new players and bringing existing players back.
  • Gamesys Group plc is the parent company of an online group that provides entertainment to a global consumer base.

International Patent Reviews Releases Study on Sun Pharmaceuticals' LEVULAN® KERASTICK® patent

Retrieved on: 
Monday, July 26, 2021
Patent law, Pharmaceuticals policy, Monopoly, Patent, Pharmaceutical industry in China, United States patent law, Chemical patent, Articles, Outline of patents

DALLAS, July 26, 2021 /PRNewswire/ -- Today, International Patent Reviews, LLC (IPR) released a study on Sun Pharmaceuticals' U.S. Patent No.

Key Points: 
  • DALLAS, July 26, 2021 /PRNewswire/ -- Today, International Patent Reviews, LLC (IPR) released a study on Sun Pharmaceuticals' U.S. Patent No.
  • However, many pharmaceutical filings are purposefully structured to artificially extend the reach of protection afforded by our patent system."
  • IPR has developed a comprehensive and multifaceted process for identifying pharmaceutical patent filings that have taken advantage of the patent system.
  • The first patent for LEVULAN KERASTICK was issued in January of 1992.

The Advanced Vehicle PatentBook™ Defines 21st Century Patent Licensing

Retrieved on: 
Monday, July 26, 2021
Monopoly, Patent law, Patent, Patent pools, Access Advance

PatentBooks are the world's most efficient patent licensing platform, providing patent owners and users the ability to license and profit from autonomous and electric vehicle patents.

Key Points: 
  • PatentBooks are the world's most efficient patent licensing platform, providing patent owners and users the ability to license and profit from autonomous and electric vehicle patents.
  • Tens of thousands of patents Published to the Advanced Vehicle PatentBook are available for Subscribers to license with a single click.
  • According to PatentBooks' Founder and CEO, Art Nutter, "The Advanced Vehicle PatentBook revolutionizes the way both patent owners and patent users license patents, allowing them to innovate and profit easily and predictably.
  • PatentBooks is a revolutionary, simplified, convenient patent licensing platform for both patent owners and patent users.

Mammoth Energy Services, Inc. Announces 2021 Second Quarter Earnings Release and Conference Call Schedule

Retrieved on: 
Friday, July 23, 2021
Monopoly, Public utility, NASDAQ, Mammoth, Prehistoric mammals, Finance, Service industries

OKLAHOMA CITY, July 23, 2021 (GLOBE NEWSWIRE) -- Mammoth Energy Services, Inc. (NASDAQ: TUSK) (the Company), announced today that it will disclose its 2021 second quarter financial results on Friday, July 30, 2021 at 6:00 a.m. Eastern Time.

Key Points: 
  • OKLAHOMA CITY, July 23, 2021 (GLOBE NEWSWIRE) -- Mammoth Energy Services, Inc. (NASDAQ: TUSK) (the Company), announced today that it will disclose its 2021 second quarter financial results on Friday, July 30, 2021 at 6:00 a.m. Eastern Time.
  • In conjunction with the earnings release, the Company has scheduled a conference call and webcast to discuss second quarter results the same day at 9:00 a.m. Eastern Time (8:00 a.m. Central Time).
  • Mammoth is an integrated, growth-oriented infrastructure services company focused on the construction and repair of the electric grid for private utilities, public investor-owned utilities and co-operative utilities through its infrastructure services businesses.
  • Mammoths suite of services and products include: infrastructure services, well completion services, natural sand and proppant services, drilling services and other energy services.

Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101

Retrieved on: 
Thursday, July 22, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Monopoly, Patent law, Patent, GOCOVRI, Adamas, GOCOVRI, ADAMAS

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announces the issuance of two patents covering GOCOVRI (amantadine) extended-release capsules: U.S. Patent No.

Key Points: 
  • Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announces the issuance of two patents covering GOCOVRI (amantadine) extended-release capsules: U.S. Patent No.
  • With the issuance of these two patents, Adamas portfolio of patents for GOCOVRI now includes 17 U.S. patents across four separate patent families that will expire from 2025 to 2038.
  • Adamas previously announced settlement agreements with first filers for both available strengths of GOCOVRI, granting non-exclusive licenses from March 4, 2030, or earlier in certain circumstances.
  • In addition to these two new patents for GOCOVRI, Adamas recently received a new patent covering ADS-4101, its investigational drug candidate being considered for partnering opportunities.

Blue Biofuels Files 3 Additional Patents on its CTS Technology

Retrieved on: 
Wednesday, July 21, 2021
Intellectual property law, Monopoly, Patent, Patent law, United States patent law, Outline of patents

Alliance BioEnergy Plus Inc., DBA Blue Biofuels, (the Company) is pleased to announce that it filed 3 additional patents that follow on the granted patent to its Cellulose-to-Sugar (CTS) technology system.

Key Points: 
  • Alliance BioEnergy Plus Inc., DBA Blue Biofuels, (the Company) is pleased to announce that it filed 3 additional patents that follow on the granted patent to its Cellulose-to-Sugar (CTS) technology system.
  • In the process of testing and perfecting towards commercialization, the Company has developed additional unique technology related to its CTS system to file for the multiple additional patents.
  • These three patents are in addition to the primary granted patent and one other patent pending, making it five in total.
  • The patents show continuous technological achievement and development and ensures that the company is in full ownership of its core technology.